Threat Landscape
Healthcare carries the highest single-incident breach cost of any industry. And the consequences are not measurable in dollars alone.
The 2024 healthcare cybersecurity year is defined by a single event: the February 2024 ransomware attack on Change Healthcare, a UnitedHealth Group subsidiary that processes approximately one in three US healthcare claims. The attackers — affiliated with the BlackCat / ALPHV ransomware-as-a-service operation — gained access on February 12, encrypted files on February 21, and exfiltrated the protected health information of an estimated 192.7 million individuals. The breach took out the country's largest healthcare claims-processing platform for over a month, disrupting prescription processing, insurance verification, and provider payment across the entire US healthcare system. [01]
The Change Healthcare incident accounted for 69% of the year's total breached records. Even excluding that single incident, 2024 saw approximately 85 million healthcare records breached — itself a record-equivalent year. The 14 mega-breaches affecting more than 1 million records each collectively exposed 237.9 million records, equivalent to 69.97% of the US population. [02]
In 2024, healthcare breaches affected an average of 792,226 individuals every day. In 2024, healthcare cybersecurity spend rose. The two facts coexist.
The Verizon 2024 DBIR identified errors as responsible for 45% of healthcare-industry breaches, with personal health information commonly exposed. Misuse of privilege was also significant. Hacking and other IT incidents dominated, accounting for 81.2% of large 2024 breaches and at least 259 million breached records. The average size of a hacking incident in 2024 was 439,796 records.
The threat-actor profile in healthcare differs from finance. Where financial-sector adversaries are dominantly financially motivated criminal groups, healthcare attracts a wider mix: financially motivated ransomware operators (who pay attention to the sector's reduced ability to refuse payment given patient-safety implications), nation-state actors (who target pharmaceutical R&D and clinical-trial data), and insiders.